Board approves direct listing of existing shares on NSE Main Board

Capital Market Events View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹96.60

prior close

₹96.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+6.2% vs market

Pharmaceuticals peers, median of 174sector+1.2%+5.4% vs sector

On the reaction day the stock moved 6.2 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6+0.4+6.2+1.2+5.4

Next day

+6.6+2.1+4.5+3.1+3.5

+7.2+2.2+5.0+4.7+2.5

+6.6+2.9+3.8+4.7+2.0

+3.0pendingpending+3.4-0.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On October 24, 2026, the board approved applying to NSE to list the company’s entire existing paid-up equity share capital on the NSE Main Board through the direct listing route. The plan remains subject to NSE and other necessary approvals.

Likely market impact

Successful listing could improve visibility and investor access, but timing and approval remain uncertain.